Back to 
BAKER BROS. ADVISORS LP
BAKER BROS. ADVISORS LP
NBIXShowing 0 of 14 quarters
Position history for BAKER BROS. ADVISORS LP's holdings in NEUROCRINE BIOSCIENCES INC
No. Baker Bros. Advisors exited its NBIX (Neurocrine Biosciences) position in Q2 2022. Its Q1 2022 13F listed 676,975 shares worth $63.5M. Baker Bros. Advisors already held NBIX in its Q1 2019 13F, the earliest on record, and held it in 13 quarterly 13F filings.
Current Value
-
Current Shares
-
Total Value Change
$0
Total Shares Change
0
No position history available for this security.
Other major holders of NBIX: BlackRock, Inc., BlackRock Finance, Inc.